As of 2026-01-05, the EV/EBITDA ratio of 10X Genomics Inc (TXG) is -15.97. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TXG's latest enterprise value is 1,670.75 mil USD. TXG's TTM EBITDA according to its financial statements is -104.60 mil USD. Dividing these 2 quantities gives us the above TXG EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 18.6x | 15.6x |
| Forward P/E multiples | 20.8x - 21.4x | 21.0x |
| Fair Price | (13.78) - (11.94) | (11.71) |
| Upside | -182.9% - -171.8% | -170.4% |
| Date | EV/EBITDA |
| 2026-01-02 | -15.97 |
| 2025-12-31 | -15.60 |
| 2025-12-30 | -15.57 |
| 2025-12-29 | -15.40 |
| 2025-12-26 | -15.81 |
| 2025-12-24 | -16.06 |
| 2025-12-23 | -15.83 |
| 2025-12-22 | -16.36 |
| 2025-12-19 | -15.28 |
| 2025-12-18 | -15.22 |
| 2025-12-17 | -14.92 |
| 2025-12-16 | -14.87 |
| 2025-12-15 | -14.93 |
| 2025-12-12 | -14.57 |
| 2025-12-11 | -15.88 |
| 2025-12-10 | -17.07 |
| 2025-12-09 | -17.45 |
| 2025-12-08 | -17.00 |
| 2025-12-05 | -17.36 |
| 2025-12-04 | -17.82 |
| 2025-12-03 | -17.48 |
| 2025-12-02 | -17.57 |
| 2025-12-01 | -17.74 |
| 2025-11-28 | -18.62 |
| 2025-11-26 | -18.55 |
| 2025-11-25 | -18.94 |
| 2025-11-24 | -20.22 |
| 2025-11-21 | -18.05 |
| 2025-11-20 | -15.78 |
| 2025-11-19 | -14.80 |
| 2025-11-18 | -14.69 |
| 2025-11-17 | -14.86 |
| 2025-11-14 | -15.09 |
| 2025-11-13 | -15.65 |
| 2025-11-12 | -16.06 |
| 2025-11-11 | -15.94 |
| 2025-11-10 | -16.53 |
| 2025-11-07 | -14.31 |
| 2025-11-06 | -11.59 |
| 2025-11-05 | -12.19 |
| 2025-11-04 | -12.03 |
| 2025-11-03 | -12.44 |
| 2025-10-31 | -12.37 |
| 2025-10-30 | -10.92 |
| 2025-10-29 | -11.47 |
| 2025-10-28 | -12.00 |
| 2025-10-27 | -12.31 |
| 2025-10-24 | -12.52 |
| 2025-10-23 | -12.03 |
| 2025-10-22 | -10.70 |